Copernicus Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Copernicus Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$386K	Buy	+15,000	New	+$356K	4.67%	9

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Copernicus Capital Management's ALLO Position: Q3 2021 in Review

Copernicus Capital Management opened a new position in Allogene Therapeutics (ALLO) in Q3 2021: 15,000 shares worth $386K. The stake represents 4.67% of the portfolio and ranks #9 among its holdings.

169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

Copernicus Capital Management held 15,000 shares of Allogene Therapeutics worth $386K as of Q3 2021.
Allogene Therapeutics was a new Copernicus Capital Management position in Q3 2021.
Allogene Therapeutics made up 4.67% of Copernicus Capital Management's portfolio in Q3 2021, its #9 holding.
169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.